Clinical Oversight Review Board (CORB-FAST) Criteria for Prescribing/
Criteria-Based Consultation (CBC) Criteria for Coverage

semaglutide (Wegovy)

Notes:
- Quantity Limits: No
- ^ Adequate trial is defined as a 3-month treatment duration
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- Patients with no coverage for medications used for weight loss or those who choose to pay full price will be excluded from the review process

Non-Formulary semaglutide (Wegovy) requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-formulary semaglutide (Wegovy) will be covered on the prescription drug benefit for 4 months when the following criteria are met:

- Diagnosis for chronic weight management; AND
- Patient is 18 years of age or older; AND
- Patient’s current weight and BMI are documented in the encounter in which semaglutide (Wegovy) is ordered; AND
- Patient is currently following a diet and exercise program; AND
- BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² AND has at least one of the following comorbid conditions documented:
  - Hypertension
  - Diabetes
  - Hyperlipidemia
  - AND -
- Patient has failed an adequate trial^ to at least one of the following medications or medication combination therapies, or patient has an allergy, intolerance, or contraindication to all the following therapies:
  - phentermine
  - Qsymia
  - Phentermine + topiramate
  - Contrave
  - naltrexone + bupropion
  - Plenity
Clinical Oversight Review Board (CORB-FAST) Criteria for Prescribing/Criteria-Based Consultation (CBC) Criteria for Coverage

semaglutide (Wegovy)

**Continued use criteria (4 months after initiation and then every 12 months):** Non-formulary semaglutide (Wegovy) will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient’s updated weight and BMI are recently documented; **AND**
- Patient has achieved > 5% weight loss with the past 16 weeks from initiation (reviewed once); **OR**
- Maintains >5% weight loss thereafter (reviewed every 12 months)

**Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:** Non-formulary semaglutide (Wegovy) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

Patient is using for chronic weight management